Neurophysiological Biomarkers for Lewy Body Dementias

Overview

Journal Clin Neurophysiol

Publisher Elsevier

Specialties Neurology
Psychiatry

Date 2015 Jul 18

PMID 26183755

Citations 15

Authors

Ruth A Cromarty

Greg J Elder

Sara Graziadio

Mark Baker

Laura Bonanni

Marco Onofrj

John T OBrien

John-Paul Taylor

Affiliations

Soon will be listed here.

Abstract

Objective: Lewy body dementias (LBD) include both dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD), and the differentiation of LBD from other neurodegenerative dementias can be difficult. Currently, there are few biomarkers which might assist early diagnosis, map onto LBD symptom severity, and provide metrics of treatment response. Traditionally, biomarkers in LBD have focussed on neuroimaging modalities; however, as biomarkers need to be simple, inexpensive and non-invasive, neurophysiological approaches might also be useful as LBD biomarkers.

Methods: In this review, we searched PubMED and PsycINFO databases in a semi-systematic manner in order to identify potential neurophysiological biomarkers in the LBDs.

Results: We identified 1491 studies; of these, 37 studies specifically examined neurophysiological biomarkers in LBD patients. We found that there was substantial heterogeneity with respect to methodologies and patient cohorts.

Conclusion: Generally, many of the findings have yet to be replicated, although preliminary findings reinforce the potential utility of approaches such as quantitative electroencephalography and motor cortical stimulation paradigms.

Significance: Various neurophysiological techniques have the potential to be useful biomarkers in the LBDs. We recommend that future studies focus on maximising the diagnostic specificity and sensitivity of the most promising neurophysiological biomarkers.

Citing Articles

Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer's Disease: A Pragmatic Review for Clinicians.

Wyman-Chick K, Chaudhury P, Bayram E, Abdelnour C, Matar E, Chiu S Neurol Ther. 2024; 13(3):885-906.

PMID: 38720013 PMC: 11136939. DOI: 10.1007/s40120-024-00620-x.

The high cost of care and limited evidence on cost-effective strategies for Lewy body dementia: systematic review of evidence.

Boland E, Fitzpatrick R, Ryan D, Kane J, Betzhold S, Leroi I BJPsych Open. 2024; 10(1):e20.

PMID: 38179602 PMC: 10790215. DOI: 10.1192/bjo.2023.626.

Early detection of Parkinson's disease: Systematic analysis of the influence of the eyes on quantitative biomarkers in resting state electroencephalography.

Gimenez-Aparisi G, Guijarro-Estelles E, Chornet-Lurbe A, Ballesta-Martinez S, Pardo-Hernandez M, Ye-Lin Y Heliyon. 2023; 9(10):e20625.

PMID: 37829809 PMC: 10565694. DOI: 10.1016/j.heliyon.2023.e20625.

EEG-Derived Functional Connectivity Patterns Associated with Mild Cognitive Impairment in Parkinson's Disease.

Pelaez Suarez A, Berrillo Batista S, Pedroso Ibanez I, Casabona Fernandez E, Fuentes Campos M, Chacon L Behav Sci (Basel). 2021; 11(3).

PMID: 33806841 PMC: 8005012. DOI: 10.3390/bs11030040.

The Role of EEG in the Diagnosis, Prognosis and Clinical Correlations of Dementia with Lewy Bodies-A Systematic Review.

Law Z, Todd C, Mehraram R, Schumacher J, Baker M, LeBeau F Diagnostics (Basel). 2020; 10(9).

PMID: 32825520 PMC: 7555753. DOI: 10.3390/diagnostics10090616.

References

de Waal H, Stam C, Blankenstein M, Pijnenburg Y, Scheltens P, van der Flier W . EEG abnormalities in early and late onset Alzheimer's disease: understanding heterogeneity. J Neurol Neurosurg Psychiatry. 2010; 82(1):67-71. DOI: 10.1136/jnnp.2010.216432. View

Hanagasi H, Bilgic B, Emre M . Neuroimaging, biomarkers, and management of dementia with lewy bodies. Front Neurol. 2013; 4:151. PMC: 3791548. DOI: 10.3389/fneur.2013.00151. View

Fujishiro H, Ferman T, Boeve B, Smith G, Graff-Radford N, Uitti R . Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol. 2008; 67(7):649-56. PMC: 2745052. DOI: 10.1097/NEN.0b013e31817d7a1d. View

Mukaetova-Ladinska E, Monteith R, Perry E . Cerebrospinal fluid biomarkers for dementia with lewy bodies. Int J Alzheimers Dis. 2010; 2010:536538. PMC: 2965495. DOI: 10.4061/2010/536538. View

Dodel R, Csoti I, Ebersbach G, Fuchs G, Hahne M, Kuhn W . Lewy body dementia and Parkinson's disease with dementia. J Neurol. 2008; 255 Suppl 5:39-47. DOI: 10.1007/s00415-008-5007-0. View

Engedal K, Snaedal J, Hoegh P, Jelic V, Andersen B, Naik M . Quantitative EEG Applying the Statistical Recognition Pattern Method: A Useful Tool in Dementia Diagnostic Workup. Dement Geriatr Cogn Disord. 2015; 40(1-2):1-12. DOI: 10.1159/000381016. View

Adler G, Brassen S, Jajcevic A . EEG coherence in Alzheimer's dementia. J Neural Transm (Vienna). 2003; 110(9):1051-8. DOI: 10.1007/s00702-003-0024-8. View

Lim X, Yeo J, Green A, Pal S . The diagnostic utility of cerebrospinal fluid alpha-synuclein analysis in dementia with Lewy bodies - a systematic review and meta-analysis. Parkinsonism Relat Disord. 2013; 19(10):851-8. DOI: 10.1016/j.parkreldis.2013.06.008. View

Oranje B, Geyer M, Bocker K, Kenemans J, Verbaten M . Prepulse inhibition and P50 suppression: commonalities and dissociations. Psychiatry Res. 2006; 143(2-3):147-58. DOI: 10.1016/j.psychres.2005.11.002. View

10.

Bronnick K, Nordby H, Larsen J, Aarsland D . Disturbance of automatic auditory change detection in dementia associated with Parkinson's disease: A mismatch negativity study. Neurobiol Aging. 2008; 31(1):104-13. DOI: 10.1016/j.neurobiolaging.2008.02.021. View

11.

Bosboom J, Stoffers D, Stam C, Berendse H, Wolters E . Cholinergic modulation of MEG resting-state oscillatory activity in Parkinson's disease related dementia. Clin Neurophysiol. 2009; 120(5):910-5. DOI: 10.1016/j.clinph.2009.03.004. View

12.

Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M . EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain. 2008; 131(Pt 3):690-705. DOI: 10.1093/brain/awm322. View

13.

Celebi O, Temucin C, Elibol B, Saka E . Short latency afferent inhibition in Parkinson's disease patients with dementia. Mov Disord. 2012; 27(8):1052-5. DOI: 10.1002/mds.25040. View

14.

Taylor J, Firbank M, Barnett N, Pearce S, Livingstone A, Mosimann U . Visual hallucinations in dementia with Lewy bodies: transcranial magnetic stimulation study. Br J Psychiatry. 2011; 199(6):492-500. PMC: 3227808. DOI: 10.1192/bjp.bp.110.090373. View

15.

Francis P . Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD. J Neurol. 2009; 256 Suppl 3:280-5. DOI: 10.1007/s00415-009-5247-7. View

16.

Babiloni C, Percio C, Bordet R, Bourriez J, Bentivoglio M, Payoux P . Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer's disease patients. Clin Neurophysiol. 2012; 124(5):837-50. DOI: 10.1016/j.clinph.2012.09.017. View

17.

Cantone M, Pino G, Capone F, Piombo M, Chiarello D, Cheeran B . The contribution of transcranial magnetic stimulation in the diagnosis and in the management of dementia. Clin Neurophysiol. 2014; 125(8):1509-32. DOI: 10.1016/j.clinph.2014.04.010. View

18.

Liedorp M, van der Flier W, Hoogervorst E, Scheltens P, Stam C . Associations between patterns of EEG abnormalities and diagnosis in a large memory clinic cohort. Dement Geriatr Cogn Disord. 2008; 27(1):18-23. DOI: 10.1159/000182422. View

19.

Ziemann U . TMS and drugs. Clin Neurophysiol. 2004; 115(8):1717-29. DOI: 10.1016/j.clinph.2004.03.006. View

20.

Marra C, Quaranta D, Profice P, Pilato F, Capone F, Iodice F . Central cholinergic dysfunction measured "in vivo" correlates with different behavioral disorders in Alzheimer's disease and dementia with Lewy body. Brain Stimul. 2011; 5(4):533-8. DOI: 10.1016/j.brs.2011.08.009. View